Evolent Health, Inc (NYSE:EVH) Receives $15.85 Consensus Price Target from Analysts

Evolent Health, Inc (NYSE:EVH) has been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $15.8462.

Several equities analysts recently commented on the company. Truist Financial upped their target price on Evolent Health from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Stephens reiterated an “equal weight” rating and issued a $9.00 target price on shares of Evolent Health in a research note on Wednesday, September 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolent Health in a research note on Wednesday, October 8th. Zacks Research lowered Evolent Health from a “hold” rating to a “strong sell” rating in a research note on Friday, October 10th. Finally, BTIG Research restated a “buy” rating and set a $20.00 price target on shares of Evolent Health in a research note on Tuesday, September 30th.

Institutional Investors Weigh In On Evolent Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its stake in Evolent Health by 88.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after acquiring an additional 1,194 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in shares of Evolent Health in the first quarter valued at about $25,000. Parallel Advisors LLC grew its stake in shares of Evolent Health by 82.6% in the second quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company’s stock valued at $39,000 after buying an additional 1,577 shares in the last quarter. Strs Ohio acquired a new stake in shares of Evolent Health in the first quarter valued at about $47,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Evolent Health in the second quarter valued at about $58,000.

Evolent Health Stock Performance

Evolent Health stock opened at $7.82 on Wednesday. The firm has a market capitalization of $918.34 million, a P/E ratio of -4.85 and a beta of 0.66. The stock has a fifty day moving average price of $8.71 and a 200 day moving average price of $9.24. Evolent Health has a 52 week low of $7.06 and a 52 week high of $25.22. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72.

Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, June 4th. The technology company reported $0.21 EPS for the quarter. The firm had revenue of $427.70 million during the quarter. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%. Equities research analysts anticipate that Evolent Health will post 0.08 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.